Comprehensive proteomic and transcriptomic analysis reveals early induction of a protective anti‐oxidative stress response by low‐dose proteasome inhibition

Effective inhibition of the proteasome by high doses of proteasome inhibitors induces apoptotic cell death. In contrast, partial proteasome inhibition by low inhibitor doses mediates a protective cellular stress response. The early targets and mediators of these dose‐dependent effects of proteasome inhibitors are unknown. Primary human umbilical cord vein endothelial cells were treated with low and high doses of the proteasome inhibitor MG132 for 2 h. In a combined 2‐DE and MS approach, we identified more than 20 new targets of proteasome inhibition. These proteins are involved in cell cycle regulation, signaling, cytoskeletal rearrangement, and cellular stress response. Accompanying Affymetrix analysis revealed that these proteins are not regulated on the transcriptional level but are mainly stabilized by proteasome inhibition. The proteasome‐dependent accumulation of the anti‐oxidative sensor proteins DJ‐1, peroxiredoxin‐1 and ‐6 was accompanied by dose‐dependent induction of oxidative stress after 2 h of proteasome inhibition and contributed to the differential transcriptional stress response to low‐ and high‐dose proteasome inhibition: Whereas low‐dose proteasome inhibition induces a transcriptional profile reminiscent of a physiological stress response that preconditions and protects endothelial cells from oxidative stress, high inhibitor doses induce massive transcriptional dysregulation and pronounced oxidative stress triggering apoptosis.

[1]  C. Richter-Landsberg,et al.  Proteasome inhibition by MG‐132 induces apoptotic cell death and mitochondrial dysfunction in cultured rat brain oligodendrocytes but not in astrocytes , 2006, Glia.

[2]  O. Zolk,et al.  Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. , 2007, Biochemical and biophysical research communications.

[3]  R. Huber,et al.  Structure of 20S proteasome from yeast at 2.4Å resolution , 1997, Nature.

[4]  M. Sherman,et al.  Proteasome Inhibitors Activate Stress Kinases and Induce Hsp72 , 1998, The Journal of Biological Chemistry.

[5]  T. Reinheckel,et al.  Degradation of oxidized proteins in mammalian cells , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  A. Iwamatsu,et al.  Variants of peroxiredoxins expression in response to hydroperoxide stress. , 2001, Free radical biology & medicine.

[7]  P. Kloetzel,et al.  Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. , 2004, Current opinion in immunology.

[8]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[9]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Cristine Alves da Costa DJ-1: a newcomer in Parkinson's disease pathology. , 2007, Current molecular medicine.

[11]  Jeffrey N Keller,et al.  Proteasome Inhibition Alters Neural Mitochondrial Homeostasis and Mitochondria Turnover* , 2004, Journal of Biological Chemistry.

[12]  Tomoya Kinumi,et al.  Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. , 2004, Biochemical and biophysical research communications.

[13]  P. Kloetzel,et al.  Ubiquitin-Proteasome Pathway as a New Target for the Prevention of Restenosis , 2002, Circulation.

[14]  H. Holzhütter,et al.  Evidence for the Existence of a Non-catalytic Modifier Site of Peptide Hydrolysis by the 20 S Proteasome* , 2000, The Journal of Biological Chemistry.

[15]  Daniel Figeys,et al.  Proteomic analysis of ubiquitinated proteins from human MCF-7 breast cancer cells by immunoaffinity purification and mass spectrometry. , 2005, Journal of proteome research.

[16]  K. Itoh,et al.  Selective Induction of the Tumor Marker Glutathione S-Transferase P1 by Proteasome Inhibitors*[boxs] , 2005, Journal of Biological Chemistry.

[17]  S. Rhee,et al.  Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. , 2005, Free radical biology & medicine.

[18]  Elaine H. J. Yew,et al.  Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro‐apoptotic transcriptional responses: a microarray analysis , 2005, Journal of neurochemistry.

[19]  J. Taylor,et al.  Selective Accumulation of Aggregation-Prone Proteasome Substrates in Response to Proteotoxic Stress , 2009, Molecular and Cellular Biology.

[20]  D. Neri,et al.  Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study , 2004, Proteomics.

[21]  S. Hoffmann,et al.  Role and Function of the 26S Proteasome in Proliferation and Apoptosis , 2002, Laboratory Investigation.

[22]  Mark A. Wilson,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .

[23]  G. Petsko,et al.  The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.

[24]  G. Atweh,et al.  The role of stathmin in the regulation of the cell cycle , 2004, Journal of cellular biochemistry.

[25]  A. Goldberg,et al.  Proteasome Inhibition Leads to a Heat-shock Response, Induction of Endoplasmic Reticulum Chaperones, and Thermotolerance* , 1997, The Journal of Biological Chemistry.

[26]  T. Smith,et al.  J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. , 1991, Biochemistry.

[27]  G. Baumann,et al.  Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. , 2006, Free radical biology & medicine.

[28]  R. Brigelius-Flohé,et al.  The GI-GPx Gene Is a Target for Nrf2 , 2005, Molecular and Cellular Biology.

[29]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[30]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[31]  C. A. D. Costa,et al.  DJ-1: a newcomer in Parkinson's disease pathology. , 2007, Current molecular medicine.

[32]  A. Ciechanover,et al.  Ubiquitin‐mediated proteolysis: biological regulation via destruction , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[33]  M. Muratani,et al.  How the ubiquitin–proteasome system controls transcription , 2003, Nature Reviews Molecular Cell Biology.

[34]  V. Labas,et al.  Proteomic study of human umbilical vein endothelial cells in culture , 2003, Proteomics.

[35]  L. Murphy,et al.  The Prohibitins: emerging roles in diverse functions , 2006, Journal of cellular and molecular medicine.

[36]  K. Stangl,et al.  Proteasome inhibitors: Poisons and remedies , 2008, Medicinal research reviews.

[37]  Lei Zhang,et al.  Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI , 2007, Brain Research.

[38]  N. Munshi,et al.  Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. , 2007, Blood.

[39]  P. Elliott,et al.  Proteasome inhibition: a new anti-inflammatory strategy , 2003, Journal of Molecular Medicine.

[40]  D. McConkey,et al.  Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. , 2005, Cancer research.

[41]  L. Papa,et al.  Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death , 2007, Apoptosis.

[42]  G. Baumann,et al.  Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. , 2005, Biochemical pharmacology.

[43]  R. Seifert,et al.  Analysis by high-resolution two-dimensional electrophoresis of differentiation-dependent alterations in cytosolic protein pattern of HL-60 leukemic cells. , 1990, Journal of biochemical and biophysical methods.

[44]  J. Karlsson,et al.  The Proteasome and Intracellular Redox Status: Implications for Apoptotic Regulation in Lens Epithelial Cells , 2007, Current eye research.

[45]  E. Niki,et al.  Proteomic characterization of oxidative dysfunction in human umbilical vein endothelial cells (HUVEC) induced by exposure to oxidized LDL , 2005, Free radical research.

[46]  J. Klose Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues , 1975, Humangenetik.

[47]  C. Bartsch,et al.  Long‐term up‐regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.